Once vs. twice-daily lopinavir/ritonavir in HIV-1-infected children

被引：6

作者：

Lyall, H. ^{[1
]}

Inshaw, J. ^{[1
]}

Saidi, Y. ^{[1
]}

Cressey, T. R. ^{[1
]}

Forcat, S. ^{[1
]}

Riault, Y. ^{[1
]}

Bastiaans, D. ^{[1
]}

Burger, D. ^{[1
]}

Koenigs, C. ^{[1
]}

Kanjanavanit, S. ^{[1
]}

Nayagam, D. ^{[1
]}

Bunupuradah, T. ^{[1
]}

Oliveira, R. Hugo ^{[1
]}

della Negra, M. ^{[1
]}

Giaquinto, C. ^{[1
]}

Babiker, A. G. ^{[1
]}

Compagnucci, A. ^{[1
]}

Gibb, D. M. ^{[1
]}

Goodall, R. L. ^{[1
]}

机构：

[1] UCL, Clin Trials Unit, London WC2B 6NH, England

来源：

AIDS | 2015年 / 29卷 / 18期

关键词：

children; HIV-1; lopinavir/ritonavir; once daily; randomized; trial; ONCE-DAILY REGIMEN; TABLET FORMULATION; PHARMACOKINETICS; LOPINAVIR; RITONAVIR; PLASMA; TOLERABILITY; NONINFERIOR; DRUGS;

D O I：

10.1097/QAD.0000000000000862

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Objective:To evaluate whether once daily (q.d.) lopinavir/ritonavir is noninferior to twice daily (b.i.d.) dosing in children.Design:International, multicentre, phase II/III, randomized, open-label, noninferiority trial (KONCERT/PENTA18/ANRS150). Setting:Clinical centres participating in the PENTA, HIV-NAT and PHPT networks.Participants:Children/adolescents with HIV-1 RNA viral load less than 50 copies/ml for at least 24 weeks on lopinavir/ritonavir-containing antiretroviral therapy.Intervention:Children were randomized to continue lopinavir/ritonavir b.i.d. or change to q.d. Main outcome measure:Confirmed viral load 50copies/ml by 48 weeks (12% noninferiority margin). Results:One hundred seventy-three children were randomized in the KONCERT trial (86 q.d., 87 b.i.d.); 46% men, median (IQR) age 11 (9-14) years, CD4% 33 (27-38)%. By week 48, 97 and 98% of time was spent on q.d. and b.i.d., respectively (one q.d. child lost at week 4). Twelve q.d. vs. seven b.i.d. children had confirmed viral load 50copies/ml within 48 weeks; estimated difference in percentage with viral load rebound 6% [90% CI (-2, 14)]. Numbers of children with grade 3/4 adverse events (11 vs. 7) or major resistance mutations (3 vs. 2) were similar, q.d. vs. b.i.d. (both P > 0.3). Among 26 children in an intrasubject lopinavir/ritonavir pharmacokinetic substudy, lower daily exposure (AUC(0-24) 161 h.mg/l vs. 224 h.mg/l) and lower C-last (1.03mg/l vs. 5.69mg/l) were observed with q.d. vs. b.i.d. dosing. Conclusion:Noninferiority for viral load suppression on q.d. vs. b.i.d. lopinavir/ritonavir was not demonstrated. Although results, therefore, do not support routine use of q.d. lopinavir/ritonavir, lack of safety concerns or resistance suggest that q.d. dosing remains an option in selected, adherent children, with close viral load monitoring. Copyright (C) 2015 Wolters Kluwer Health, Inc. All rights reserved.

引用

页码：2447 / 2457

页数：11

共 27 条

[1]

AbbVie Limited, 2014, KAL 200 MG 50 MG FIL

[2]

AbbVieLimited, 2011, 3089639 ABBVIELIMITE

[3]

[Anonymous], 1994, MMWR Recomm Rep, V43, P1

[4] Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life [J].

Bamford, A. ;

Turkova, A. ;

Lyall, H. ;

Foster, C. ;

Klein, N. ;

Bastiaans, D. ;

Burger, D. ;

Bernadi, S. ;

Butler, K. ;

Chiappini, E. ;

Clayden, P. ;

Della Negra, M. ;

Giacomet, V. ;

Giaquinto, C. ;

Gibb, D. ;

Galli, L. ;

Hainaut, M. ;

Koros, M. ;

Marques, L. ;

Nastouli, E. ;

Niehues, T. ;

Noguera-Julian, A. ;

Rojo, P. ;

Rudin, C. ;

Scherpbier, H. J. ;

Tudor-Williams, G. ;

Welch, S. B. .

HIV MEDICINE, 2018, 19 (01) :e1-e42

[5] Pharmacokinetics of Pediatric Lopinavir/ Ritonavir Tablets in Children When Administered Twice Daily According to FDA Weight Bands [J].

Bastiaans, Diane E. T. ;

Forcat, Silvia ;

Lyall, Hermione ;

Cressey, Tim R. ;

Hansudewechakul, Rawiwan ;

Kanjanavanit, Suparat ;

Noguera-Julian, Antoni ;

Koenigs, Christoph ;

Inshaw, Jamie R. J. ;

Chalermpantmetagul, Suwalai ;

Saidi, Yacine ;

Compagnucci, Alexandra ;

Harper, Lynda M. ;

Giaquinto, Carlo ;

Colbers, Angela P. H. ;

Burger, David M. .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2014, 33 (03) :301-305

[6] Second-line protease inhibitor-based HAART after failing non-nucleoside reverse transcriptase inhibitor-based regimens in Asian HIV-infected children [J].

Bunupuradah, Torsak ;

Puthanakit, Thanyawee ;

Fahey, Paul ;

Kariminia, Azar ;

Yusoff, Nik K. N. ;

Khanh, Truong H. ;

Sohn, Annette H. ;

Chokephaibulkit, Kulkanya ;

Lumbiganon, Pagakrong ;

Hansudewechakul, Rawiwan ;

Razali, Kamarul ;

Kurniati, Nia ;

Huy, Bui V. ;

Sudjaritruk, Tavitiya ;

Kumarasamy, Nagalingeswaran ;

Fong, Siew M. ;

Saphonn, Vonthanak ;

Ananworanich, Jintanat .

ANTIVIRAL THERAPY, 2013, 18 (04) :591-598

[7] The International Interlaboratory Quality Control Program for Measurement of Antiretroviral Drugs in Plasma: A Global Proficiency Testing Program [J].

Burger, David ;

Teulen, Marga ;

Eerland, Jaco ;

Harteveld, Anneke ;

Aarnoutse, Rob ;

Touw, Daan .

THERAPEUTIC DRUG MONITORING, 2011, 33 (02) :239-243

[8]

Carpenter J, 2000, STAT MED, V19, P1141, DOI 10.1002/(SICI)1097-0258(20000515)19:9<1141::AID-SIM479>3.0.CO

[9]

2-F

[10] Once- versus twice-daily lopinavir/ritonavir tablets in virologically suppressed, HIV-infected, treatment-experienced children: comparative pharmacokinetics and virological outcome after switching to once-daily lopinavir/ritonavir [J].

Chokephaibulkit, Kulkanya ;

Nuntarukchaikul, Maneeratn ;

Phongsamart, Wanatpreeya ;

Wittawatmongkol, Orasri ;

Lapphra, Keswadee ;

Vanprapar, Nirun ;

Cressey, Tim R. .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2012, 67 (12) :2927-2931

← 1 2 3 →